Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

GHRP2 Dosage: Research Protocols & Why We Don’t Prescribe

Back to library
peptide

GHRP2 Dosage: Research Protocols & Why We Don’t Prescribe

15 min read
GHRP-2
GH Secretagogue
Mechanism of Action
Research Protocols
Last Updated: May 2026

When researchers search “GHRP2 dosage,” they are almost always looking for one of two things: the dose parameters from published clinical research, or prescriptive guidance for personal use — and those are not the same thing, and only one of them is something we can provide. This article covers what GHRP-2 actually is, how it works at the receptor level, what the published clinical and diagnostic research has used in documented study protocols, how GHRP-2 compares to Ipamorelin and GHRP-6 as research tools, and why Pure Grade Labs explains the science without prescribing. For researchers who need GHRP-2 or CJC-1295+DAC for growth hormone axis research, the GH Optimization Research Stack provides both at verified research grade. All products are for laboratory research only. Not for human consumption.

GHRP2 (also written GHRP-2 with a hyphen) is a ghrelin mimetic that agonises the growth hormone secretagogue receptor (GHSR-1a), stimulating endogenous GH release. Its pharmacological profile — including documented cortisol and prolactin elevation alongside GH stimulation — makes it a biologically active and research-relevant compound that deserves accurate characterisation, not vague marketing language or irresponsible prescriptive claims.

Key Takeaways

  • GHRP-2 (Pralmorelin) is a synthetic hexapeptide ghrelin mimetic with CAS 158861-67-7 and MW 817.98 Da. It agonises GHSR-1a to stimulate endogenous GH release in a dose-dependent manner.
  • Clinical research by Bowers et al. (1998) documented significant GH pulse in healthy adults at IV doses of 1 µg/kg, with dose-dependent response up to ~30 µg/kg. Concomitant cortisol and prolactin elevation was documented at higher doses.
  • The Pralmorelin stimulation test — a diagnostic protocol used in Japan and some European medical centres — uses a standardised dose of 2 µg/kg IV to assess GH axis function. This is a documented clinical dose from published diagnostic protocols, not prescriptive advice from this article.
  • GHRP-2 differs from Ipamorelin in a key respect: GHRP-2 causes cortisol and prolactin elevation alongside GH stimulation; Ipamorelin is highly selective for GH release with minimal cortisol or prolactin effect. This selectivity distinction is the central differentiator for research design.
  • Pure Grade Labs supplies GHRP-2 10mg at ≥99% HPLC purity with batch-specific COA for laboratory research. We explain the science — we do not prescribe.
6
Amino acids in GHRP-2 — a synthetic hexapeptide, making it one of the smallest compounds in the GH secretagogue research class
1 µg/kg
IV dose at which Bowers et al. (1998) documented significant GH pulse in healthy adults — the threshold for published GH axis activity in research subjects
2 µg/kg
IV dose used in the Pralmorelin (GHRP-2) GH stimulation diagnostic test — the standardised clinical protocol for GH axis assessment in Japan and European centres
3
Key GH secretagogues compared in research: GHRP-2 (cortisol + prolactin elevation), GHRP-6 (strongest hunger effect), Ipamorelin (most selective — minimal off-target effects)

GHRP-2 — Research-Grade Supply for GH Axis Studies

≥99% HPLC purity. Batch-specific COA. Lyophilised powder. For laboratory research only.

Source GHRP-2 10mg for Your Research →

What Is GHRP-2 (Pralmorelin)?

GHRP-2 — also written GHRP2 without the hyphen, and formally known as Pralmorelin — is a synthetic hexapeptide belonging to the growth hormone secretagogue (GHS) research class. It was developed in the laboratory of Cyril Bowers, who pioneered the GHRP compound family over several decades of GH axis research. GHRP-2 is a ghrelin mimetic: it binds to and activates the same receptor as ghrelin (the Growth Hormone Secretagogue Receptor type 1a, GHSR-1a), stimulating pituitary release of endogenous growth hormone.

GHRP2 is structurally distinct from natural ghrelin — it is a synthetic hexapeptide (six amino acids) rather than the 28-amino acid acylated peptide, and its compact structure confers robust receptor binding affinity and resistance to enzymatic degradation, properties that make it a practical research tool for GH axis investigation.

GHRP-2 Molecular Profile

Parameter Value
Full Name Growth Hormone Releasing Peptide-2 (Pralmorelin)
CAS Number 158861-67-7
Molecular Weight 817.98 Da
Amino Acid Count 6 (hexapeptide)
Sequence D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂
Receptor Target GHSR-1a (Growth Hormone Secretagogue Receptor type 1a)
Compound Class Ghrelin mimetic; synthetic GH secretagogue

GHRP-2 Mechanism of Action: GHSR-1a Agonism

The mechanism of GHRP-2 is well-characterised in the literature. As a GHSR-1a agonist, it binds to the growth hormone secretagogue receptor — primarily expressed in the pituitary and hypothalamus — and triggers a signalling cascade that culminates in the pulsatile release of growth hormone from anterior pituitary somatotroph cells. This is the same receptor pathway that natural ghrelin activates, making GHRP-2 a synthetic ghrelin mimetic with defined receptor pharmacology.

Critically, GHRP-2 acts on an endogenous pulsatile release pathway rather than introducing exogenous GH. This mechanistic distinction is what has made GHRP compounds valuable as research tools for studying GH axis regulation: the physiological GH response they elicit can be studied in a controlled, dose-dependent context. The GH pulse produced by GHRP-2 is amplified by the simultaneous presence of GHRH (Growth Hormone Releasing Hormone), which is the synergistic basis behind research combinations pairing GHRP-2 with CJC-1295+DAC (a long-acting GHRH analogue).

The Documented Adverse Hormonal Profile

One of the defining characteristics of GHRP2 in published research is its documented off-target hormonal effects. Alongside GH stimulation, GHRP-2 has been shown to elevate both cortisol and prolactin in research subjects — an adverse profile documented by Bowers et al. (1998) and confirmed in subsequent studies. This is not an incidental finding; it reflects GHSR-1a’s distribution across multiple tissue types beyond the pituitary and hypothalamus. The cortisol and prolactin elevation associated with GHRP-2 — particularly at higher doses — is a central reason why researchers comparing GH secretagogues often contrast it against the more selective compound Ipamorelin, which was specifically developed to achieve GH release with minimal cortisol and prolactin response.

What Published Research Protocols Have Studied: GHRP2 Dosage in Clinical Context

When researchers search “GHRP2 dosage,” the published evidence base is the correct reference point — not practitioner forums or anecdotal reports. Here is what the documented clinical and preclinical research literature has actually examined:

Bowers et al. (1998) — Dose-Response Characterisation

In foundational work published in the Journal of Pediatric Endocrinology and Metabolism, Bowers CY et al. (1998) characterised the GH response to intravenous GHRP-2 in healthy adult subjects. At IV doses of 1 µg/kg, a statistically significant GH pulse was documented. The response was dose-dependent, extending up to approximately 30 µg/kg IV, at which dose cortisol and prolactin elevation were also well-documented alongside the GH response. This represents the primary published data characterising the GH secretagogue dose-response relationship for GHRP-2 in human research subjects. These are data points from published research — not prescriptive recommendations.

The Pralmorelin Stimulation Test — A Documented Diagnostic Protocol

Perhaps the most relevant published context for GHRP2 dosage research is the Pralmorelin stimulation test — a standardised diagnostic protocol used in Japan and select European medical centres for the assessment of growth hormone deficiency. The test uses a standardised IV administration of GHRP-2 (Pralmorelin) at 2 µg/kg body weight, followed by serial GH measurements to assess GH axis responsiveness. This is a documented clinical application published in diagnostic endocrinology literature — it is cited here as factual documentation of published medical practice, not as prescriptive advice for any reader of this article. The Pralmorelin test has been validated as a diagnostic tool precisely because GHRP-2’s GHSR-1a agonism provides a standardised, reproducible GH axis stimulus.

Why We Explain This and Do Not Prescribe

Pure Grade Labs is a research chemical supplier. We explain the mechanism of action, the published clinical research, and the documented study parameters because these are matters of public scientific record — they are in the literature and relevant to researchers working in the GH axis space. We do not tell anyone to “take X mg of GHRP-2” because we are not a medical practice, we are not providing personalised medical advice, and we do not supply compounds for human consumption. The distinction is clear and it matters: researchers deserve accurate information about the compounds they work with. People seeking self-administration guidance should consult a qualified medical professional — not a research peptide supplier.

GHRP-2 and CJC-1295+DAC — GH Axis Research Supply

Both compounds available individually or in the GH Optimization Research Stack. ≥99% HPLC purity. Batch COA included. Research chemicals only.

View GH Optimization Research Stack →

GHRP-2 vs Ipamorelin in Research: The Selectivity Question

The comparison between GHRP-2 and Ipamorelin is one of the most studied questions in the GH secretagogue research literature, and the central finding is straightforward: GHRP-2 is more potent in its GH release but less selective; Ipamorelin is highly selective for GH release with minimal effect on cortisol and prolactin.

Raun et al. (1998) — the landmark paper characterising Ipamorelin — specifically addressed this selectivity comparison. GHRP-2 causes dose-dependent cortisol and prolactin elevation alongside GH release; Ipamorelin produces GH release at equivalent potency without the cortisol or prolactin signal. For research designs where the investigator wants to study isolated GH axis effects without confounding adrenocortical or lactotrophic activation, Ipamorelin offers a cleaner experimental tool. For research designs where the full GHSR-1a signalling profile — including cortisol and prolactin responses — is itself the subject of investigation, GHRP-2 provides that broader physiological stimulus.

GH Secretagogue Comparison: GHRP-2, Ipamorelin, GHRP-6

Parameter GHRP-2 Ipamorelin GHRP-6
Receptor GHSR-1a GHSR-1a (selective) GHSR-1a
GH Release Potency High High Moderate–High
Cortisol Elevation Documented (dose-dependent) Minimal / not documented Moderate
Prolactin Elevation Documented Minimal / not documented Moderate
Hunger/Appetite Effect Intermediate Minimal Strongest (most pronounced)
Research Selectivity Broad GHSR profile + off-targets Highest selectivity for GH release Moderate — ghrelin effects prominent
Best Research Application GH axis + adrenocortical/lactotrophic axis co-investigation Isolated GH axis studies, clean GH secretagogue model Ghrelin/hunger axis studies, appetite-related research

GHRP-2 vs GHRP-6: Comparative Research Considerations

GHRP-6 is a different compound from GHRP-2 — they share the same receptor target (GHSR-1a) and the same hexapeptide structure class, but their amino acid sequences differ, and their biological profiles diverge in clinically meaningful ways. The most prominent difference in the published literature is appetite stimulation: GHRP-6 produces the strongest hunger and appetite-stimulating effect of the three primary GHRPs studied (GHRP-2, GHRP-6, and Ipamorelin). This is attributed to GHRP-6’s stronger ghrelin-mimetic character — ghrelin itself is orexigenic (appetite-promoting), and GHRP-6 preserves more of that signalling character than GHRP-2 does.

GHRP-2 produces an intermediate hunger response — more pronounced than Ipamorelin, less pronounced than GHRP-6. For researchers specifically studying appetite and orexigenic pathways, GHRP-6 is the more appropriate model compound. For researchers studying GH secretion with less interference from appetite signalling, GHRP-2 or Ipamorelin offer progressively cleaner research models. This selectivity hierarchy — GHRP-6 → GHRP-2 → Ipamorelin, from broadest to most selective — is well-established in the preclinical literature and should inform compound selection for any GH axis research design.

GHRP-2 + CJC-1295+DAC: GH Axis Research Combination

GH secretagogue research consistently demonstrates that GHRP compounds and GHRH analogues act synergistically on GH release — a finding that is mechanistically logical, since they activate two distinct but complementary pathways in pituitary somatotroph signalling. GHRP-2 agonises GHSR-1a to initiate GH release; CJC-1295+DAC (a GHRH analogue with extended half-life via Drug Affinity Complex technology) provides sustained GHRH receptor activation that amplifies the GH pulse. In research models, the combined administration of a GHRP and a GHRH analogue produces significantly greater GH elevation than either compound alone — a synergistic effect well-documented in the preclinical and early clinical literature.

This is the mechanistic rationale behind the GH Optimization Research Stack from Pure Grade Labs, which provides both GHRP-class and GHRH-class compounds for researchers investigating GH axis amplification. The stack is designed for researchers who need both components of the GH secretagogue / GHRH synergy model in a single research combination purchase.

Research Applications: Where GHRP-2 Is Studied

The published literature on GHRP-2 and related secretagogues covers several research domains. The primary research area is endocrinology — specifically GH axis regulation, pituitary responsiveness, and the characterisation of somatotroph function. The Pralmorelin stimulation test has been used diagnostically to assess GH deficiency, positioning GHRP-2 as a research tool in endocrine diagnostic methodology as well as basic science.

Beyond GH axis characterisation, GHRP-2 research has explored cardiac and tissue contexts — the GH / IGF-1 axis that GHRP compounds stimulate has downstream relevance for multiple metabolic and anabolic research contexts. Metabolic researchers studying GH secretion in models of ageing, GH deficiency, or GH axis dysfunction have used GHRP compounds including GHRP-2 as pharmacological tools to manipulate GH secretion in controlled experimental settings.

Pure Grade Labs supplies GHRP-2 10mg as lyophilised powder for laboratory research, at ≥99% HPLC-verified purity with batch-specific COA. Researchers needing the full GH secretagogue research toolkit can browse all available research compounds or source the GH Optimization Research Stack for the combined GHRP + GHRH research combination.

A researcher reviewing the GH secretagogue literature for a study on somatotroph responsiveness encountered the same pattern that many researchers find: a large volume of online commentary about “GHRP2 dosage” that ranges from anecdote to forum speculation, and a much smaller but more reliable body of peer-reviewed evidence. The Bowers et al. (1998) dose-response characterisation, the Raun et al. (1998) Ipamorelin selectivity comparison, and the published Pralmorelin stimulation test literature provide a coherent, citable pharmacological picture of what GHRP-2 does at specific dose ranges, in which contexts, and with what measured hormonal outcomes. That is what a research compound’s “dosage” discussion should look like — not prescriptive protocol advice, but documented evidence. The researcher sourced GHRP-2 and Ipamorelin from Pure Grade Labs — both at ≥99% HPLC purity with batch-specific COAs — and designed their experimental matrix based on the published dose-response data.

Frequently Asked Questions

What is GHRP-2 used for in research?

GHRP-2 (Pralmorelin) is used in research primarily for GH axis investigation — including characterisation of somatotroph responsiveness, GH pulse studies, and as a diagnostic tool in the Pralmorelin stimulation test for GH deficiency assessment. It is also used in comparative secretagogue research alongside Ipamorelin and GHRP-6 to study selectivity differences. All uses referenced here are in laboratory or clinical research contexts.

What does the published research say about GHRP2 dosage?

Bowers et al. (1998) documented significant GH pulse at IV doses of 1 µg/kg in healthy research subjects, with dose-dependent response up to ~30 µg/kg. The Pralmorelin stimulation test — a published clinical diagnostic protocol — uses a standardised dose of 2 µg/kg IV. These are data points from published medical literature, cited here as documented research findings. They are not prescriptive dosing advice from Pure Grade Labs.

What is the difference between GHRP-2 and Ipamorelin?

Both GHRP-2 and Ipamorelin agonise GHSR-1a and stimulate GH release. The key difference is selectivity: GHRP-2 also produces dose-dependent cortisol and prolactin elevation alongside GH release; Ipamorelin is highly selective for GH release with minimal documented effect on cortisol or prolactin (Raun et al., 1998). For research requiring isolated GH axis stimulation without adrenocortical or lactotrophic confounders, Ipamorelin is the more selective tool.

What is the Pralmorelin stimulation test?

The Pralmorelin stimulation test is a standardised clinical diagnostic procedure used primarily in Japan and some European medical centres to assess GH axis function. It involves IV administration of Pralmorelin (GHRP-2) at a standardised 2 µg/kg dose, followed by serial GH measurements. GH response below a defined threshold indicates GH deficiency. This is documented medical practice published in the endocrinology literature; it is cited here as contextual research information, not as a protocol recommendation.

Why doesn’t Pure Grade Labs give dosing protocols for GHRP-2?

Pure Grade Labs is a research chemical supplier. We supply compounds for laboratory research, not for human consumption. Providing personalised dosing protocols would be prescribing — a medical act that requires appropriate qualifications and regulatory authorisation. We explain the published science accurately, so that researchers have a reliable information base. People seeking human use guidance should consult a qualified medical professional.

Can GHRP-2 and CJC-1295 be used in the same research protocol?

Yes — GHRP compounds and GHRH analogues act synergistically in published research models because they activate distinct and complementary receptor pathways. GHRP-2 agonises GHSR-1a; CJC-1295+DAC agonises the GHRH receptor. In combination, published research documents significantly amplified GH release versus either compound alone. Both are available together in the GH Optimization Research Stack.

GHRP-2 and the Full GH Secretagogue Research Range

GHRP-2, Ipamorelin, CJC-1295+DAC — all at ≥99% HPLC purity. Batch COA with every order. For laboratory research only.

Browse All Research Compounds →

Summary: GHRP-2 Dosage — Research Protocols and the Science

GHRP-2 (GHRP2 / Pralmorelin) is a synthetic hexapeptide GH secretagogue with CAS 158861-67-7 and MW 817.98 Da. It agonises GHSR-1a to stimulate endogenous GH release in a dose-dependent, pulsatile manner — the same receptor pathway used by natural ghrelin. Its documented profile includes cortisol and prolactin elevation alongside GH release at higher research doses, distinguishing it from the more selective Ipamorelin and making it a distinct research tool for GH axis studies where the full GHSR-1a signalling profile is under investigation.

Published research documents GH pulse responses from IV doses as low as 1 µg/kg (Bowers et al., 1998). The Pralmorelin stimulation test — used diagnostically in Japan and European centres — uses a standardised 2 µg/kg IV dose to assess GH axis function. These are published medical data points, cited here as documented research findings. Pure Grade Labs explains what the literature says — we do not prescribe. Researchers seeking GH axis compound supply will find GHRP-2 10mg, Ipamorelin 10mg, CJC-1295+DAC 10mg, and the GH Optimization Research Stack all available at ≥99% HPLC purity with batch-specific COA.

The selectivity hierarchy across GH secretagogues — from GHRP-6 (broadest, strongest appetite signal) through GHRP-2 (intermediate) to Ipamorelin (most selective for GH, minimal off-target effects) — is one of the most practically useful frameworks in this research class. Understanding that hierarchy, grounded in published comparative data from Raun et al. (1998) and Bowers et al. (1998), allows researchers to select the appropriate tool for their specific experimental design rather than defaulting to the most commonly discussed compound.

References

  1. Bowers CY, Alster DK, Frentz JM. The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. J Clin Endocrinol Metab. 1998;83(11):3817–3821. doi:10.1210/jcem.83.11.5250
  2. Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316–1329. doi:10.1007/s000180050262
  3. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. doi:10.1530/eje.0.1390552
  4. Popovic V, Leal A, Micic D, et al. GH-releasing hormone and GH-releasing peptide-2 frequently elicit discordant GH responses: significance of the GHRP-2 test for the diagnosis of GH deficiency. Eur J Endocrinol. 2000;143(4):472–479. doi:10.1530/eje.0.1430472
  5. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–660. doi:10.1038/45230
  6. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472–1479. doi:10.1210/jcem.82.5.3947
  7. Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445–460. doi:10.1530/eje.0.1360445
  8. Katakami H, Arimura A, Frohman LA. Growth hormone (GH)-releasing factor stimulates hypothalamic somatostatin release: an inhibitory feedback effect on GH secretion. Endocrinology. 1986;118(3):1872–1877. doi:10.1210/endo-118-3-1872

Research Use Only. GHRP-2 and all products supplied by Pure Grade Labs are sold strictly as research chemicals for in vitro and preclinical laboratory use. They are not intended for human consumption, veterinary use, or any use outside of a controlled laboratory research setting. Nothing in this article constitutes medical advice, dosing guidance, or a recommendation for human use. References to published clinical protocols and diagnostic test doses are factual citations from the peer-reviewed literature — they are not prescriptive advice or endorsements of human use. Pure Grade Labs makes no therapeutic claims. Researchers are responsible for complying with all applicable regulations in their jurisdiction. Not suitable for use outside of a professional research context.